ArticleDiscover oncology2025
Causal association between inflammatory markers and malignant neoplasms of bone and articular cartilage using Mendelian randomization.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe pathogenesis of malignant neoplasms of bone and articular cartilage is not fully understood, as the inflammatory immune microenvironment may play a crucial role in tumor development and progression. This study aimed to investigate the causal associations between specific inflammatory immune markers and the risk of bone and articular cartilage malignancies.
methodsOn the basis of genome-wide association study (GWAS) data from inflammatory factors and blood metabolites, single nucleotide polymorphisms (SNPs) with F statistics greater than 10 were selected as valid instrumental variables. Mendelian randomization (MR) methodology was employed to assess causal relationships between inflammatory markers and bone tumor risk, with sensitivity analyses conducted via MR‒Egger, heterogeneity tests, leave-one-out analysis, and MR-PRESSO. Additionally, qRT-PCR was used to validate the expression of key markers in cell lines.
resultsMendelian randomization analysis revealed that elevated CXCL6 levels were positively correlated with tumor occurrence risk (OR = 1.5, 95% CI: 1.1–2.0), while MIP (OR = 0.5, 95% CI: 0.3–0.7), CCL4 (OR = 0.6, 95% CI: 0.4–0.8), and LIF-R (OR = 0.5, 95% CI: 0.3–0.8) were significantly associated with reduced tumor risk. Sensitivity analyses confirmed robust results with no significant horizontal pleiotropy. Meta-analysis showed CCL4 expression was reduced in most studies, while CXCL6 was significantly upregulated in tumor tissues. qRT-PCR validation demonstrated that all four inflammatory markers were significantly higher in tumor cell lines compared to normal cells (P < 0.01).
conclusionThis study, which uses Mendelian randomization, suggests potential causal associations between inflammatory immune markers and the risk of malignant neoplasms of bone and articular cartilage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.